---
title: CDMO Daily News — July 11, 2026
slug: daily-news-2026-07-11-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: July 11 CDMO daily: FDA Proposes Streamlined Registration for Distributed Manufacturing and Foreign Drug Suppliers; FDA FRAME Initiative Establishes…
canonical_url: https://cdmo.directory/posts/daily-news-2026-07-11-cdmo
published_at: 2026-07-11T00:01:11.337Z
last_updated: 2026-07-11T00:02:12.762Z
---

### FDA Proposes Streamlined Registration for Distributed Manufacturing and Foreign Drug Suppliers
- FDA proposed rule would allow distributed manufacturing establishments using hub-and-spoke models to register as a single entity instead of registering each unit separately, reducing administrative burden.
- Rule clarifies that foreign drug manufacturers—including API suppliers serving only other foreign facilities—must register with FDA, closing a supply-chain visibility gap.
- Changes expected to reduce registration costs for distributed manufacturers and improve FDA's real-time oversight of drug manufacturing locations and upstream supply sources.

**Operational Impact**

CDMO operators using distributed or hub-and-spoke manufacturing models will benefit from consolidated registration and streamlined unit-change notifications, while those sourcing foreign APIs must ensure upstream suppliers register with FDA to maintain supply-chain compliance.

*Source: [FDA Press Releases RSS](https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-modernize-drug-manufacturing-registration)*

---

### FDA FRAME Initiative Establishes Regulatory Framework for Advanced Manufacturing Technologies
- FDA's CDER issued a proposed rule in July 2026 for drug establishment registration requirements covering distributed manufacturing and foreign establishments.
- FRAME initiative prioritizes four advanced technologies: end-to-end continuous manufacturing, distributed manufacturing at non-traditional sites, and AI-driven systems.
- FDA is harmonizing global regulatory expectations through ICH guidelines (including Q13 on continuous manufacturing) and issuing updated guidance on compliance with 21 CFR 211.110.

**Operational Impact**

CDMOs implementing end-to-end continuous manufacturing, distributed units at healthcare facilities, or AI-driven process control must now comply with the July 2026 proposed registration rule and align validation strategies with FDA's updated 21 CFR 211.110 guidance and emerging ICH Q13 standards.

*Source: [FDA What's New Drugs RSS](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cders-framework-regulatory-advanced-manufacturing-evaluation-frame-initiative)*

## References

1. [FDA Press Releases RSS — FDA Proposes Streamlined Registration for Distributed Manufacturing and Foreign Drug Suppliers](https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-modernize-drug-manufacturing-registration)
2. [FDA What's New Drugs RSS — FDA FRAME Initiative Establishes Regulatory Framework for Advanced Manufacturing Technologies](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cders-framework-regulatory-advanced-manufacturing-evaluation-frame-initiative)

Source: https://cdmo.directory/posts/daily-news-2026-07-11-cdmo